Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Novartis Pharmaceuticals
Femme et Homme Max 99 ans
Novartis Pharmaceuticals
MAJ Il y a 5 ans
Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Omalizumab in Japanese Children (6 - 15 Years)
To examine whether the geometric mean of serum free IgE level at 24 weeks of the treatment period in Japanese pediatric patients reaches under 25 ng/mL (target level).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharmaceuticals
MAJ Il y a 5 ans
Efficacy and Safety of Fluvastatin or Valsartan and Their Combination in Dyslipidemic Patients With Hypertension and Endothelial Dysfunction
Patients with mild to moderate hypertension, dyslipidemia (imbalanced blood lipids) and decreased vascular dilatation, receiving a cholesterol lowering diet were given either valsartan or ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharmaceuticals Ltd (UK)
MAJ Il y a 5 ans
A descriptive study of Relapsing-Remitting Multiple Sclerosis (RRMS) treated with first disease modifying therapies (DMTs) in current UK clinical practice: patterns of clinical decision making and the patient experience of relapse
Background and study aims This is a research study being carried out at six hospitals in the UK. It will look back over 3 years at how well patients with multiple sclerosis (MS) respond to medicines k...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharmaceuticals
MAJ Il y a 5 ans
This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload
changes in ferritin level, compared to baseline, in patients with transfusion-induced iron overload treated with Exjade (Time Frame: Baseline assessment is followed by monthly assessments for up to 1 ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme Max 99 ans
Novartis Pharmaceuticals UK Ltd
MAJ Il y a 5 ans
A one year, open label, multi-center, extension study to CHTF919D2301 to assess the long term safety of tegaserod 6 mg bid given orally in female patients with symptoms of dyspepsia
To evaluate the long gterm safety of tegaserod (6mg bid) at 6 months in female patients with symptoms of dyspepsia
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharmaceuticals
MAJ Il y a 5 ans
Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma
• Rate of Clinically Significant Asthma Exacerbations Per Patient in the 24-week Fixed-dose Steroid • Percentage of Participants With at Least 1 Adverse Event
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharmaceuticals UK Ltd
MAJ Il y a 5 ans
A 52-week extension to a multicenter, randomized, double-blind, active controlled study to compare the effect of 52 weeks treatment with LAF237 50 mg bid to metformin up to 1000 mg bid in drug naïve patients with type 2 diabetes
Primary 1. To assess the long-term safety of LAF237 compared to metformin during 104 weeks of treatment. 2. To assess the long-term efficacy of LAF237 compared to metformin by evaluating the effect on...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharmaceuticals UK Ltd (UK) - unconditional block grant (ref: COLO400A 2423)
MAJ Il y a 5 ans
Ciclosporin and azathioprine treatment in severe ulcerative colitis: a double-blind controlled trial to evaluate short and long-term outcome
Not provided at time of registration
Pays
United Kingdom
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharmaceuticals
MAJ Il y a 5 ans
Post Hematopoietic Stem Cell Transplantation
•Safety of deferasirox in the treatment of iron overload after HSCT in patients with beta-thalassemia major [ Time Frame: 12 months ] • To determine the safety; incidence, type and severity of advers...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharmaceuticals UK Ltd
MAJ Il y a 5 ans
An extension to a phase II study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome-positive leukemia including acute lymphoblastic leukaemia, acute myeloid leukaemia, and accelerated phase chronic myeloid leukemia
•To enable patients to have access to study drug and continue study treatment •To decrease data collection to include overall survival and serious adverse events
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
1
2
3
4
5
6
7
Suivant